DNA titers, and changes in the British Isles Lupus Assessment Group scores for organ system manifestations (no worsening in renal components, and improvements in mucocutaneous components). A decrease in the prednisone dose and increase in C3 levels had very minor impacts on the total LuMOS score. In all analyses of the BLISS-76 and BLISS-52 trial data sets, the mean LuMOS scores were significantly higher (P < 0.0001) in patients treated with 1 mg or 10 mg belimumab compared to placebo. In contrast to the performance of the SLE Responder Index 4 (SRI-4), the LuMOS revealed significant differences between the active treatment group (1 mg belimumab in the BLISS-76 cohort) and placebo group. The effect sizes were significantly much higher with the LuMOS than with the SRI-4.
Conclusion. The evidenced-based LuMOS outcome scoring system, developed with data from the BLISS-76 trial of belimumab in patients with SLE and validated with data from the BLISS-52 trial, exhibits a superior capacity to discriminate responders from nonresponders when compared to the SRI-4. Use of the LuMOS may improve the efficiency and power of analyses in future lupus trials.
Randomized controlled trials (RCTs) of new treatments for systemic lupus erythematosus (SLE) are hampered by the lack of an effective outcome measure that is both responsive to change and clinically relevant (1, 2) . Although most recent lupus trials have employed the SLE Disease Activity Index (SLEDAI) (3) or British Isles Lupus Assessment Group (BILAG) index of disease activity in organ-based systems (4) or have used composite outcomes based on these instruments, experience has demonstrated that performance of these outcome measures is less than ideal. The instruments are complicated to use and based on recall information and not merely on events present at the time of the clinical encounter, and their responsiveness to change has been questioned. Furthermore, they are not widely used in clinical practice, and therefore the relevance of either of these instruments to the clinician as a measure of change is problematic. Despite these caveats, both the SLEDAI and the BILAG scoring systems are extensively used in RCTs assessing treatment response in patients with lupus, largely because of the absence of proven alternative measures.
One challenge is that the multifactorial nature of SLE and the inherent heterogeneity of the patients enrolled in RCTs make it difficult to identify a single outcome measure that would capture potential treatmentinduced improvements in the trial participants. Such characteristic heterogeneity may also be the reason that responder indices that may have performed well in the training data set (i.e., data used to develop a specific measure) will often fail to discriminate consistently between responders and nonresponders in an independent validation data set, as has been recently reported (5) .
These considerations prompted our current study, in which we aimed to develop and validate a novel Lupus Multivariable Outcome Score (LuMOS). In this study, we attempted to address the issue of patient heterogeneity by developing a multivariable response score that aggregates the information conveyed by different variables, each of which measures change in a specific component or measure of SLE disease activity. We addressed the comparative effectiveness of the LuMOS by postulating that the responsiveness to change of alternative outcome measures can be compared by assessing the extent to which they are able to discriminate the observed outcomes between patients receiving a placebo and those receiving an active treatment for lupus. In particular, to develop the new evidence-based LuMOS and validate it in an independent data set, we reanalyzed the raw data from 2 pivotal trials, the Study of Belimumab in Subjects with SLE 76-week (BLISS-76) and 52-week (BLISS-52) trials (6, 7) , the results of which were the basis of the US Food and Drug Administration (FDA) approval of belimumab for the treatment of SLE.
PATIENTS AND METHODS
Data sources. The raw data collected in the BLISS-52 and BLISS-76 RCTs were obtained from GlaxoSmithKline through their open data access program. In both trials, participants were randomized to 1 of 3 treatment arms: 1) high-dose belimumab (10 mg/kg), 2) low-dose belimumab (1 mg/kg), or 3) placebo. The background treatment was standard of care medications. Initially, the new LuMOS formula was developed using the data from the BLISS-76 trial (6) . The BLISS-52 trial data (7) were then used for external validation. Definitions of all study variables are found in the original reports of the trials (6, 7) .
Development and validation of the LuMOS. The novel LuMOS scoring system was developed through multivariable logistic regression analyses of the changes in selected variables during 52 weeks as observed in 273 SLE patients randomized to receive the high dose of belimumab (10 mg/kg) in contrast to that observed in 275 SLE patients randomized to receive placebo in the BLISS-76 trial (6) . Based on the face validity of these data, changes in scores on the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) version of the SLEDAI (8), prednisone dose, and 3 clinical biomarkers (levels of C3, C4, and anti-double-stranded DNA [antidsDNA]) were forced a priori into the final multivariable model. Additional variables were selected through a backward elimination procedure, with the minimum Akaike's information criterion (AIC) used as the selection criterion (9) . The resulting LuMOS scores were then evaluated in an independent data set that was not used to develop the LuMOS, the BLISS-52 trial data set (7), for external validation analyses and also for comparison to performance of scores on the SLE Responder Index 4 (SRI-4). The BLISS-52 trial data were assessed for changes in several treatment response variables in each of the active belimumab treatment groups compared to the placebo group. Comparisons between the LuMOS and the SRI-4 scores were carried out by calculating the effect size estimates (with 95% confidence intervals [95% CIs]) (10, 11) . Details on all of the statistical methods used for derivation and validation of the LuMOS are given in Supplementary Methods (available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40522/abstract).
RESULTS

Development of the LuMOS (phase 1).
The baseline characteristics of the patients in each of the 3 trial arms are listed in Table 1 in the original BLISS-76 trial report, while Table 2 in that original report compares the groupspecific changes in different clinical and biomarker outcomes observed during the first 52 weeks after randomization (6) . For the current analysis, missing 52-week data were imputed using the last observation carried forward (LOCF) method, yielding LOCF data for 21-26% of the BLISS-76 trial participants across the 3 trial arms, and in external validation analyses, yielding LOCF data for 16-21% of the BLISS-52 trial participants (see Supplementary Methods, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40522/ abstract).
In preliminary analyses, the AIC of the multivariable model did not change when a quantitative measure of change in the SELENA-SLEDAI score was replaced by a binary indicator, a ≥4-point reduction versus a <4-point reduction in the SELENA-SLEDAI score (AIC 719.7 versus 719.4), and therefore, in further analyses, we used the binary SELENA-SLEDAI indicator to enhance consistency with the trial data reported previously (6, 7) . After having adjusted for the 5 variables selected a priori, the different model-building strategies utilized systematically identified 2 additional BILAG-based indicators: 1) an increase in the BILAG renal score (new symptoms or increased severity), and 2) a decrease in the BILAG mucocutaneous score (resolution of symptoms or decrease in their severity). Each of these BILAG-based indicators independently improved the AIC for discrimination of treatment response between patients receiving 10 mg belimumab and patients receiving placebo.
Of note, an independent, marginally nonsignificant, association of a decrease in the BILAG musculoskeletal score was selected as an indicator in some of the model-building strategies. Since the addition of the BILAG musculoskeletal item improved the AIC of the final model by only 0.5 (AIC of 717.3, compared to an AIC of 717.8 in the model without this item), which represents an amount that was much smaller than the minimum reliable reduction of~4.0 (12), our main analyses relied on a more parsimonious model in which the BILAG musculoskeletal item was excluded.
In contrast, increases or decreases in any of the other BILAG organ-specific scores, as well as changes in the global BILAG score, changes in the physician's global assessment of disease activity, and changes in selected Short Form 36 (SF-36) health status scores (composite SF-36 physical component score, or bodily pain and vitality domain scores) did not independently contribute to improving the AIC for discrimination between the 10 mg belimumab group and placebo group, and therefore these variables were not selected for the final model (data not shown). Furthermore, alternative ways of representing the changes in BILAG scores, including quantitative variables that represent the amount of change in organ-specific BILAG items or that account for only major changes and, thus, ignore differences between the BILAG C and BILAG D categories, did not improve the ability to discriminate between the active treatment group and placebo group (data not shown).
Accordingly, the final multivariable LuMOS model that was selected included changes in 7 variables, as follows: 3 binary indicators (a decrease of ≥4 points in the SELENA-SLEDAI score, a decrease in the BILAG mucocutaneous score, and an increase in the BILAG renal score) and 4 quantitative variables (change in the prednisone dose, and changes in 3 blood biomarkers [levels of C3, C4, and anti-dsDNA antibodies]). † These data were used to develop the LuMOS formula. Table 1 shows the formula developed for calculating individual LuMOS scores based on the final multivariable logistic model. Of note, although the LuMOS was developed on the basis of the changes observed between the time of trial entry (week 0) and week 52, it can be used to assess the changes observed between week 0 and any other time point during the follow-up. The score is calculated as the weighted sum of the values of the 7 aforementioned variables observed in a given subject, with calculations carried out according to the following 3 rules. Rule 1. First, the intercept is added to the scores for all subjects. In this way, it has no impact on the comparisons of individual scores or their within-group mean values.
Rule 2. For each of the 3 binary indicator variables, the respective coefficient either is added to the sum if the subject meets the corresponding condition (any of the treatment response conditions specified in Table 1 ) or is ignored (i.e., replaced by 0) if the subject does not meet the corresponding condition. Positive coefficients identify conditions more likely to occur in the active treatment group (10 mg belimumab), whereas negative coefficients indicate that the condition is more frequent among patients randomized to receive placebo.
Rule 3. For each continuous variable, the difference (change) between its value observed at a given postbaseline time point and the value at week 0 is multiplied by the corresponding coefficient. For this rule, a positive coefficient indicates that an increase (or a smaller decrease) in the value of the corresponding variable is associated with a better outcome and is therefore more likely to occur in the belimumab-treated subjects, whereas negative coefficients indicate that the active treatment is associated with decreases (or smaller increases).
Finally, the results of the calculations in rules 1-3 are summed to obtain the LuMOS score for each subject.
As shown in Table 1 , values obtained with the LuMOS were mostly driven by a meaningful reduction in disease activity (reflected by a decrease in the SELENA-SLEDAI score by ≥4 points), an increase in C4 levels, a decrease in anti-dsDNA antibody titers, and changes in 2 BILAG items, characterized by a lack of new symptoms or worsening of the renal component, and improvements in the mucocutaneous component. In contrast, changes in the prednisone dose and C3 levels had only a very minor impact on the total LuMOS score.
Validation of the LuMOS (phase 2). As shown in Table 2 , the distributions of the LuMOS scores were compared across the 3 treatment groups separately for the BLISS-76 trial data set (6) and the BLISS-52 trial data set (7) . All descriptive statistics indicate that in both trials, the 2 active treatment groups had systematically much higher LuMOS scores than did the placebo group. The fact that the 95% CIs for both belimumab groups in both trials did not overlap with the corresponding 95% CI for the placebo group indicate that these differences are statistically highly significant. Whereas the results from the BLISS-76 trial were affected by "optimistic bias," i.e., these data were the basis for derivation of the LuMOS formula (as shown in Table 1 ), it should be emphasized that the differences in the distributions of the LuMOS values were at least as large in the independent BLISS-52 trial data, which were not used to define the LuMOS.
As expected, discrimination from the placebo arm was more pronounced when LuMOS scores were evaluated in patients receiving the higher dose of belimumab (10 mg) compared to those receiving the lower dose (1 mg), thus confirming that there was a doseresponse relationship. On the other hand, within-group standard deviations were very similar in all 3 treatment arms of the same trial, reflecting the heterogeneity of individual responses among patients who received the same treatment. Furthermore, when we compared the same treatment groups between the 2 trials, we found that the mean LuMOS scores and median LuMOS scores (with interquartile ranges) were generally similar, suggesting that these data had good external validity. Table 3 shows the effect sizes for the contrasts between each belimumab treatment arm and the placebo arm in the same trial, obtained with 1) the proposed LuMOS scoring system, in comparison to 2) the SRI-4, which was used as the primary outcome measure in both trials (6,7). In addition, Table 3 shows the effect sizes for 3 SLE outcome measures that were used as secondary outcomes in both trials, based on binary indicators of 3) a decrease in the SELENA-SLEDAI score by ≥4 points or no worsening of either 4) the BILAG scores or 5) scores on the physician's global assessment of disease severity. The LuMOS yielded statistically significant effect sizes for all comparisons reported in Table 3 , as all 95% CIs excluded 0.
Because the LuMOS was developed to optimize the contrast between the 10 mg belimumab group and the placebo group in the BLISS-76 trial, the effect sizes for this specific contrast yielded an "optimistically biased" estimate for the LuMOS, which cannot be used for valid comparisons with the other outcome measures, and is reported only as a benchmark for other analyses. Nevertheless, the finding that the LuMOS yielded a significant effect size for the comparison between the 1 mg belimumab group and the placebo group in the BLISS-76 data set is of practical interest, because the 1 mg belimumab group was 1) not included in the development of the LuMOS, and 2) was not statistically significantly different from the placebo group in the original analyses in terms of the primary efficacy measure of the SRI-4 response rate and the major secondary outcome of the frequency of a ≥4-point reduction in the SELENA-SLEDAI score (see Table 2 in ref. 6 ).
Indeed, the lack of significance of either of these differences was replicated in our effect size analyses, as shown in Table 2 . In an independent validation data set (BLISS-52), the 95% CIs of the effect sizes yielded by the LuMOS did not overlap with the corresponding CIs for any other response index ( Table 3 ), suggesting that there was a statistically significant improvement in the ability to discriminate between active treatment and placebo offered by the LuMOS. However, this finding has to be interpreted with caution, because the LOCF approach tends to underestimate the standard errors, and therefore the CIs (as shown in Table 3 ) may be too narrow (13) . Nevertheless, the fact that the LuMOS-based effect sizes were systematically at least twice as great as for other response indices (Table 3) indicates its superior performance in the validation analyses, because the point estimates of effect sizes were not affected by LOCF (13) . Although in both belimumab dose groups only small effects for each of the existing SLE outcomes were demonstrated (effect sizes between 0.08 and 0.28), the LuMOS allowed us to establish a medium effect (effect size of 0.57) in patients receiving the low dose (1 mg/kg) of belimumab, and a big effect (effect size of 0.75) in patients receiving the high dose (10 mg/kg) of belimumab.
The higher values for effect size additionally imply that the tests of the treatment effects based on the LuMOS yielded much higher test statistics, and therefore the results were more highly significant than those yielded by tests based on the existing SLE outcome measures. For example, in the independent BLISS-52 data set, the t-tests for the contrasts between the mean LuMOS values in the placebo group and each belimumab dose group (1 mg and 10 mg) resulted in t-test statistics of 6.84 and 8.87, respectively (P < 0.0001 for both), and the corresponding values from the logistic regression-based Wald z-test were very similar, with z estimates of 6.28 and 7.79, respectively (P < 0.0001 for both). In contrast, for the same comparisons, the logistic regression-based Wald statistics based on the SRI-4, reconstructed from the results reported previously ( Table 2 in ref. 7) , were lower (by more than 50%) than the corresponding values based on the LuMOS, and the P values were markedly higher (z = 2.35, P = 0.0181 for comparison with 1 mg belimumab, and z = 3.04, P = 0.0048 for comparison with 10 mg belimumab).
Subgroup and sensitivity analyses. The performance of the LuMOS was similar in other validation analyses that were limited a priori to selected subgroups of patients, including 1) Native Americans and African Americans, 2) patients with no disease damage at baseline (as assessed according to a Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index [SDI] score of 0 at week 0), and 3) patients with disease damage at baseline (an SDI score of ≥1 at week 0). Specifically, in all external validation analyses, in the relevant subgroups of the BLISS-52 trial participants, the mean LuMOS values were much higher for both active treatment arms than for placebo (Table 4) . Accordingly, consistent with the main results reported in Table 3 , ‡ Biased result. Because the LuMOS was developed to optimize the contrast between the belimumab 10 mg/kg group and the placebo group in the BLISS-76 trial, the effect size for this specific contrast is "optimistically biased" away from the null, and should not be interpreted as a valid statistic.
ABRAHAMOWICZ ET AL
for each subgroup in the independent BLISS-52 data set, the LuMOS yielded medium-to-large effect sizes that were highly statistically significant for both belimumab groups ( Table 4) . As shown in Figure 1 , similar results were obtained in analyses limited to African American participants of the BLISS-76 trial, for whom the mean LuMOS scores were much higher in those receiving 10 mg belimumab than in those receiving placebo ( Figure 1A ). This resulted in a medium effect size based on the LuMOS (mean effect size 0.52, 95% CI 0.24, 0.80), in contrast to an absence of response according to the SRI-4 (mean effect size À0.03, 95% CI À0.32 0.26) ( Figure 1B ). Of note, in the BLISS-52 trial, there were <10 African American subjects per trial arm, thus making it impossible to carry out analyses restricted to this subgroup of BLISS-52 trial participants.
Finally, in sensitivity analyses that evaluated changes in the outcomes over different time intervals, we found that the effect sizes at only 16 weeks after treatment initiation, using the independent BLISS-52 data set, were also statistically significant (Table 5) , but these values were lower than the corresponding effects observed in the primary analyses at 52 weeks (Table 3) . In contrast, at 76 weeks, the effect sizes in the BLISS- † Missing values at the respective postbaseline time points were imputed using last observation carried forward. ‡ Results may be affected by potential "optimistic bias," as data for these subjects (at a different week) contributed to the development of the LuMOS.
LUPUS MULTIVARIABLE OUTCOME SCORE 1455 76 trial participants (Table 5) were slightly stronger than the corresponding effects calculated for 52 weeks (Table 3) . Of note, the 76-week effect size estimates using the BLISS-76 trial data were less affected by "optimistic bias," because the LuMOS was developed using only the 52-week data from this trial.
DISCUSSION
Development and validation of efficient outcome measures that are responsive to change is a priority for clinical research in SLE. Indeed, the absence of a validated, accurate responder index may reduce the ability of RCTs to establish the benefits of potentially promising new SLE treatments (1, 2, 14) . One important difficulty, rather specific to SLE trials, is related to the great heterogeneity of SLE symptoms and disease course, which implies that treatment-induced changes in individual trial participants may be reflected in different clinical characteristics and/or biomarkers (5, 15) . To address this challenge, we developed a novel evidence-based outcome scoring system, the LuMOS, as an attempt to aggregate the information on different aspects of clinically relevant changes observed in SLE patients during the trial. This approach was based on our expectation that the LuMOS will capture relevant treatment-induced changes in a number of the parameters related to SLE disease activity, thereby making it useful across a larger spectrum of the trial participants.
Similar to other recent studies, the LuMOS was derived on the basis of comparison of changes during the trial between SLE patients randomized to receive an active treatment for lupus with established effectiveness and SLE patients randomized to receive placebo (5) . Specifically, the proposed LuMOS formula was selected to maximize the discrimination between the multivariable pattern of the changes in selected outcome measures between the high dose of belimumab (10 mg/kg) and the placebo arm of the BLISS-76 trial (6), which is one of the trials that led to the FDA approval of belimumab for the treatment of SLE. The parsimonious LuMOS model with the best discriminative ability, as assessed by the AIC (9), predominantly reflected the following changes: a reduction in the SELENA-SLEDAI score by ≥4 points, an increase in C4 levels, a decrease in anti-dsDNA antibody titers, and qualitative changes in 2 BILAG items (lack of new symptoms or absence of worsening of the renal component, and improvement in the mucocutaneous component), whereas decreases in the prednisone dose and in C3 levels had only a very minor impact on the total LuMOS score. It should be noted that even though the SELENA-SLEDAI accounts for qualitative changes in 2 laboratory parameters (complement and anti-dsDNA levels), their values are dichotomized, whereas the LuMOS incorporates additional information on the quantitative amount of the changes, which, especially for C4, substantially improves the discrimination between the active treatment and placebo groups.
Validation of the LuMOS in an independent data set from the BLISS-52 trial of belimumab confirmed its ability to detect statistically significant differences in the mean LuMOS values between each of the 2 belimumab groups (1 mg/kg and 10 mg/kg) and the placebo group. Most importantly, in these independent external validation analyses, the LuMOS yielded much higher effect sizes and much lower P values than any of the existing outcome measures reported in both trials, including the original primary outcome measure of the SRI-4 (16), and changes in the SELENA-SLEDAI, BILAG, or physician's global assessment scores. These results, obtained using data that were not used to derive the new multivariable outcome measure, suggest that the LuMOS may be expected to perform well in future SLE trials, with the caveat that the LuMOS was derived and validated in separate trials of belimumab.
In addition, the LuMOS detected significant treatment effects in sensitivity analyses that used different time periods to assess changes, as well as in analyses limited to selected subpopulations, including patients who tend to be less responsive to SLE treatments, such as African Americans (6) and patients with permanent organ damage (baseline SDI score ≥1) (17) .
Finally, the LuMOS yielded statistically significant differences even for those comparisons in which conventional outcomes failed to reach significance, for example, for internal validation involving the low-dose 1 mg/kg belimumab group (not used to derive the LuMOS) in the BLISS-76 data set, for whom the primary outcome measure of the SRI-4 failed to detect a significant difference from the placebo group (6).
Our findings differ from the negative results recently reported by Forbess et al, who also queried the BLISS data sets (5). Those authors found that improvements of at least 20% on at least 4 of the 8 a priori-selected outcome measures offered statistically significant discrimination of outcomes in the active treatment group compared to the placebo group (odds ratio 2.7, 95% CI 2.0-3.6; P < 0.001) in the random learning sample, which was composed of 80% of the 1,693 patients whose data were used to define this responder index. However, the responder index scores were unable to discriminate between the same 2 groups in the remaining 20% of patients (odds ratio 1.3, 95% CI 0.8-2.2; P = 0.86). In contrast, in the current study, we successfully validated the LuMOS, even though 1) we compared placebo against the same belimumab treatment, either at the 10 mg/kg or 1 mg/kg dose, 2) we assessed the same patient population, and 3) we used data from an independent trial for external validation, which could exacerbate concerns about patients' heterogeneity. It is likely that our success in an independent validation of the LuMOS approach is related to differences in the statistical methods used in the 2 studies, including our use of continuous, rather than dichotomous, variables, and also our use of differential weighting of variables, rather than summation of variables that exceeded a prespecified threshold.
Our study has some limitations. One issue concerns the choice of the empirical criteria to define responders, which has important implications for both derivation and validation of the responder index. In the absence of a generally accepted, empirically measurable gold standard for identifying responders in SLE, we postulated that the outcomes observed in patients who received an effective FDA-approved treatment, such as high-dose belimumab, may approximate the outcome for responders. This assumption has some important implications. First, for various reasons, including disease heterogeneity and variation in background medications, some SLE patients randomized to receive belimumab do not show clinically meaningful changes. These features of trial subjects would lead to a reduced difference in the mean values for the proposed LuMOS between those patients randomized to receive belimumab and those randomized to receive placebo. From this perspective, it is unlikely that the observed performance of the LuMOS in validation analyses based on an independent data set may be "optimistically biased," i.e., overestimated.
On the other hand, change in outcomes in the trial could have been related to the specific treatment employed. Thus, a potentially more complex issue concerns the possibility that the differential weights assigned by our proposed LuMOS formula to changes in different clinically relevant variables are partly a reflection of the biochemical properties of the belimumab treatment. For example, the LuMOS assigns the strongest weight to changes in C4 levels, which may be especially influenced by belimumab treatment, owing to its effect on autoantibody production (6, 7) . If so, in a different RCT, differences in the mean LuMOS values between patients treated with a different, potentially effective drug, such as, for example, a Tcell-focused product, and those randomized to receive placebo might be smaller than the effects found in our analyses. The fact that we had access to raw data from only 2 SLE trials, both using belimumab as the active treatment, increases the importance of this concern. Furthermore, it should be emphasized that the LuMOS could employ only information collected in the trials. Thus, our analyses were limited to outcomes that were collected in the BLISS-52 and BLISS-76 trials. It is possible that collection of other biomarkers or clinical outcomes could have identified a larger set of variables that would have generated an even more effective LuMOS.
To select variables into our multivariable LuMOS model, we relied on a relatively simple approach that combined 1) a priori-chosen predictors, with selection based on substantive knowledge, with backward/forward selection of additional predictors, which added 2 BILAG-based indicators of changes in specific organs. Use of backward/forward methods raises concerns about over-fit bias, and could also increase the risk of both type I and type II errors, instability of the selection, and poor performance in the validation studies (18) (19) (20) . However, the effect size yielded by our resulting multivariable model was even better in the independent BLISS-52 validation sample ( Table 3 ), suggesting that these easy-to-implement methods had no material impact on the validity of our results. In future analyses, which will use data from SLE trials of different medications, we will implement more advanced methods that combine variable selection with shrinkage (19, 21, 22) .
Finally, to ensure comparability of the results with the original BLISS-52 and BLISS-76 trials (6,7), we imputed missing values using a conventional LOCF approach. Details on the rationale for and possible limitations of this approach (13) are provided in Supplementary Methods (available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40522/ abstract).
An important future research agenda would be to further validate the performance of the LuMOS, and compare it with alternative SLE outcome measures, using data from RCTs that have evaluated other effective SLE treatments, different than belimumab. It is notable that patient-reported outcomes did not contribute to the LuMOS value. It is possible that outcomes such as the patient's global assessment of disease severity, which was not collected in the BLISS trials, could be a contributing factor. Well-designed longitudinal cohort studies in patients with SLE could also be useful in validating the LuMOS, especially if they provide independent assessments of changes in disease activity over time. An alternative could involve validating the LuMOS against the opinions of SLE experts, using, for example, assessment of clinically plausible patient vignettes (23) . Recently, there has been interest in developing the Lupus Low Disease Activity State (LLDAS), analogous to the low disease activity target that has long been in use in patients with rheumatoid arthritis (24) . Validation of the LuMOS against the LLDAS and determining the LuMOS value that might correlate with the LLDAS value could also be of interest.
In conclusion, the encouraging results of the current study provide proof of concept for the development of a multivariable response index such as the LuMOS, and confirm its validation in an independent data set from the BLISS trial evaluating the same drug. Our findings suggest that the LuMOS may improve the power and efficiency of analyses in future SLE RCTs. However, future research will be necessary to provide additional validation analyses, especially in trials of different SLE treatments and/or different populations (for example, those with renal involvement versus those without renal involvement versus those with skin involvement). In addition, further studies aimed at refining the LuMOS formula will be needed.
